Hyperstat-CV Capsule is a combination pharmaceutical formulation containing Rosuvastatin 10 mg and Clopidogrel 75 mg, designed for the management of cardiovascular conditions. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby contributing to the prevention of atherosclerosis and related cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by selectively and irreversibly binding to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, reducing the risk of thrombotic events such as myocardial infarction, stroke, and peripheral arterial disease. The combination of these agents in Hyperstat-CV Capsule offers a synergistic approach to cardiovascular risk reduction by addressing both lipid abnormalities and platelet-mediated thrombosis. It is indicated for patients with established coronary artery disease, acute coronary syndrome, or those at high risk of cardiovascular events who require both lipid-lowering and antiplatelet therapy. Hyperstat-CV should be administered under medical supervision, with regular monitoring of lipid profiles, liver function tests, and platelet counts to ensure efficacy and safety. Caution is advised in patients with hepatic impairment, bleeding disorders, or those undergoing surgery.